Antibody-guided drug shows encouraging activity in metastatic breast cancer

A new antibody-drug compound shrank or halted the growth of metastatic breast tumours in almost half of a group of patients whose HER2-positive cancer had become resistant to standard therapies, according to early data from a multicentre Phase 2 clinical trial led by a Dana-Farber Cancer Institute researcher...

Read the whole article on

More from